BioSpace News Archive

Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in the U.K. for Nymozarfex (TM) for the treatment of benign prostatic hyperplasia (BPH).

Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. announces that the Extraordinary General Meeting of Shareholders has adopted all proposals on the EGM agenda.

The Japanese Ministry of Health, Labor, and Welfare has granted marketing authorization for ALTUVIIIO®, a first-in-class, high-sustained factor VIII replacement therapy.

BioArctic AB’s partner Eisai announced that “LEQEMBI® Intravenous Infusion” has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease.

Pierre Fabre Laboratories and Vernalis Ltd, a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.

On September 15, “Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery” successfully kicked off.

Alvotech announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd., has received marketing approval for AVT04, a biosimilar to Stelara®, from the Japanese Ministry of Health, Labor and Welfare.

Reviva Pharmaceuticals Holdings, Inc. announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia has now completed the study.

SpineThera, Inc. announced that the submitted abstract,” Clinically Meaningful Radicular Leg Pain Management via Novel Dexamethasone Extended Release Microsuspension - PH1/2 Results” has been accepted for presentation at the 22nd Annual Pain Medicine Meeting hosted by the American Society of Regional Anesthesia and Pain Medicine.

Biophytis SA and Skyepharma announce the signature of a partnership agreement for the production of regulatory batches of Sarconeos for severe forms of Covid-19, with a view to the submission of marketing authorization applications.